Yoldaş, Çelik, M.Canda, E.Yazıcı, H.Erdem, F.Özkaya, P.Y.Sahbudak, Z.B.Uçar, S.K.2024-08-252024-08-2520232757-6256https://doi.org/10.5152/TurkArchPediatr.2023.22233https://search.trdizin.gov.tr/tr/yayin/detay/1179221https://hdl.handle.net/11454/102741Objective: Coronavirus disease 2019 (COVID-19) causes significant morbidity and mortality in individuals with chronic disease. There is not enough information about the course of corona-virus disease in lysosomal storage diseases. This study aimed to evaluate coronavirus disease vaccination status and the impact of coronavirus disease on lysosomal storage disease. Materials and Methods: The study included 87 lysosomal storage disease patients. The patients’ diagnoses were Gaucher, mucopolysaccharidosis I, II, IVA, VI, VII, Fabry, and Pompe. A questionnaire assessing severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) exposure, coronavirus disease symptoms, and vaccine status was administered in person or by phone calls. Results: The number of coronavirus disease positive patients was 8 (9.1%). Only 2 patients were treated in the intensive care unit. Other coronavirus disease patients had mild symptoms and stayed in-home quarantine. Patients over 12 years of age could receive a COVID-19 vaccine. 63.5% of those aged ?12 years were vaccinated. Conclusion: Lysosomal storage disease patients did not have an increased risk of COVID-19 compared to the healthy population, despite the chronic inflammatory disease. Vaccination of lysosomal storage disease patients will be protective against severe coronavirus disease. © 2023, AVES. All rights reserved.en10.5152/TurkArchPediatr.2023.22233info:eu-repo/semantics/openAccessCOVID-19fabryGaucherinherited metabolic diseaseslysosomal storage diseasesSARS-CoV-2coronavacfavipiravirimmunoglobulinsteroidtenofoviradolescentadultanosmiaArticlechildclinical articlecoronavirus disease 2019diabetes mellitusFabry diseasefemaleGaucher diseaseheadachehospitalizationhumanhypertensioninflammatory diseaseintensive care unitleukopenialiver diseaselung diseaselysosome storage diseasemalemorbiditymortalitymucopolysaccharidosisnose smearobesitypneumoniapolymerase chain reactionquestionnairesore throatthrombocytopeniavaccinationArticle58326226711792212-s2.0-85160523823Q3